Successful explantation of children from the Berlin Heart EXCOR® ventricular assist device: A systematic review

BACKGROUND

The Berlin Heart EXCOR® (BHE) can bridge children with severe heart failure to transplantation, but some are successfully weaned and spared transplantation. This study seeks to identify characteristics of children amenable to successful explantation with BHE support.

METHODS

Preferred Reporting Items for Systematic reviews and Meta-Analyses 2020 guidelines were used. Five databases were screened for original, English articles measuring BHE support in patients <18 years old based on title and abstract. Exclusion criteria were applied: full-text availability, <10 total pediatric BHE patients, zero successful explantations from BHE, nonprimary literature, adult and pediatric results that could not be separated, and studies with overlapping patient information. Studies were analyzed with descriptive statistics.

RESULTS

From 41 857 potential studies, 14 were analyzed with data from 58 hospitals on four continents from 1990 to 2020. There were 984 BHE patients. The most common diagnosis was dilated cardiomyopathy (n = 318, 32.3%), followed by congenital heart disease (n = 249, 25.3%). There were 85 (8.6%) children explanted with favorable outcomes. The underlying diagnosis was known in 44 (51.8%) cases: 14 (8.4%) of 166 cardiomyopathies, 17 (48.6%) of 35 myocarditis, and 12 (16.7%) of 72 with congenital heart disease were explanted. When the type of support was known, the rate of LVAD patients explanted was 21.3% (n = 19/89) and 2.4% (n = 1/42) of BiVAD patients were explanted.

CONCLUSION

Explantation from BHE is not uncommon at 8.6%, but significant variation exists in the explantation data reported. Myocarditis and LVAD support may be populations suitable for weaning. Standardization of reporting measures and prospective registries may help identify patients suitable for this alternative to transplant and help develop weaning protocols.

Comparison of hollow-fiber membrane oxygenators in terms of pressure drop of the membranes during normothermic and hypothermic cardiopulmonary bypass in neonates

The objective of this study was to investigate the effects of two hollow-fiber membrane oxygenators, the Capiox SX10 and the Lilliput 901, on pressure drop of the membranes during normothermic and hypothermic cardiopulmonary bypass (CPB) in neonates.

Methods: Twenty-six congenital heart surgery patients (n=13 in each group) with a mean weight of 3 kg were included in this study. Pressure drops of the membranes, pre- and post-oxygenator extracorporeal circuit pressures (ECC) were recorded during normothermic CPB, hypothermic CPB (208C) and after rewarming. There were no differences between the groups in mean arterial pressure, pump flow rate, temperature, duration of CPB, cross- clamp time or the severity of the surgical repairs.

Results: Pressure drop of the Capiox SX10 oxygenator was significantly lower during normothermic (329/10 versus 559/16 mmHg, p B/0.001), hypothermic (389/15 versus 729/18 mmHg, p B/0.001) and post-rewarming (429/13 versus 729/21 mmHg, p B/0.001) periods compared to the Lilliput oxygenator. In the Capiox group, the pre-oxygenator ECC pressure was also significantly lower during normothermic CPB (1429/27 versus 1849/43 mmHg, p B/0.01), hypothermic CPB (1629/30 versus 1999/38 mmHg, p B/0.01) and after rewarming periods (1729/32 versus 2129/42 mmHg, p B/0.01). Post-oxygenator pressures in the Capiox group were also lower than in the Lilliput group, but results were not statistically significant.

Conclusions: These results suggest that the Capiox SX10 hollow-fiber membrane oxygenator produced significantly lower membrane pressure drops and pre- and post-oxygenator ECC during normothermic and hypothermic CPB. Thus, blood trauma with the Capiox during extracorporeal circulation may be significantly lower compared to the Lilliput. Further studies, including the level of complements, platelets, neutrophils and cytokines, with these oxygenators are warranted.

Preliminary experience with the MicroMed DeBakey pediatric ventricular assist device

Mechanical circulatory support for both acute and chronic heart failure is a widely applied therapeutic option in the adult population with a variety of devices clinically available. Technology in this field has advanced sufficiently such that long-term support or "destination therapy" has become a generally accepted reality. Similar progress has not occurred in the field of device support for heart failure in children. While the number of potential patients is significantly lower in the pediatric population, the clinical relevance and poignancy of individual need are nonetheless real. Until recently, children with heart failure have been largely disadvantaged in comparison to their adult counterparts. The DeBakey VAD Child (MicroMed Technology, Inc, Houston, TX) represents a hopeful initial step in the direction of reducing the technological gap between adults and children. While the clinical experience with this device is limited at present, preliminary results are encouraging. This report will provide an overview of the DeBakey VAD Child, including device specifications, indications for clinical use, surgical and postoperative considerations, and updated clinical experience.

Outcomes of Congenital Heart Surgery Patients After Extracorporeal Life Support at Texas Children's Hospital

The objective of this study was to investigate the outcomes of children with heart failure of various etiologies requiring temporary use of currently available technology in the U.S.A. after extracorporeal life support (ECLS) [left ventricular assist device (LVAD) or extracorporeal membrane oxygenation (ECMO)] at Texas Children's Hospital. Between July of 1995 and October of 2002, 2847 patients underwent congenital heart surgical repairs with the aid of cardiopulmonary bypass at Texas Children's Hospital. During this period, 17 patients required chronic mechanical circulatory assistance with Biomedicus centrifugal pump (n=8) or Thoratec LVAD (n=4), and ECMO (n=5). Six out of 17 patients required ECLS for postcardiotomy heart failure. Seven of the 17 patients had congenital heart disease, six had cardiomyopathy, three had late acute rejection following heart transplantation, and one had myocardial infarction. Twelve patients survived and five patients expired. Six of 12 survivors recovered sufficient cardiac function to allow device removal; and the remaining six patients underwent heart transplantation. Three out of five deaths were ECMO patients. The need for ECLS following repair of congenital heart disease is extremely rare in our institution. The requirement for the use of ECMO confers a significantly higher mortality presumably because of associated combined cardiopulmonary failure. Congenital heart disease appears to be associated with significantly higher mortality.

Phycomycosis caused by Basidiobolus haptosporus in two horses

Basidiobolus haptosporus was isolated from a horse with a rapidly progressive ulcerative lesion of the ventral midline. The pathologic findings of an irregular line of yellow material composed of hyphae, eosinophils, and granulomatous inflammation between the superficial edematous tissue and the underlying muscle, and hyphae in tissue sections intimately surrounded by granular eosinophilic cuffs were considered diagnostic for this and one other case diagnosed retrospectively. Both horses were successfully treated by surgery and potassium iodide.